Literature DB >> 27893718

FOXO3 is essential for CD44 expression in pancreatic cancer cells.

M Kumazoe1, M Takai1, J Bae1, S Hiroi1, Y Huang1, K Takamatsu1, Y Won1, M Yamashita1, S Hidaka1, S Yamashita1, S Yamada1, M Murata1, S Tsukamoto1, H Tachibana1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal types of cancer and the 5-year survival rate is only 5%. Several studies have suggested that cancer stem cells (CSCs) are thought to be involved in recurrence and metastasis and so it is essential to establish an approach targeting CSCs. Here we have demonstrated that cyclic guanosine monophosphate (cGMP) suppressed CD44 expression and the properties of CSCs in PDAC. Microarray analysis suggested that cGMP inhibited Forkhead box O3 (FOXO3), which is known as a tumor suppressor. Surprisingly, our data demonstrated that FOXO3 is essential for CD44 expression and the properties of CSCs. Our data also indicated that patients with high FOXO3 activation signatures had poor prognoses. This evidence suggested that cGMP induction and FOXO3 inhibition could be ideal candidates for pancreatic CSC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27893718     DOI: 10.1038/onc.2016.426

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a.

Authors:  Diego H Castrillon; Lili Miao; Ramya Kollipara; James W Horner; Ronald A DePinho
Journal:  Science       Date:  2003-07-11       Impact factor: 47.728

2.  Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition.

Authors:  Erwin Bischoff; Johannes-Peter Stasch
Journal:  Circulation       Date:  2004-09-21       Impact factor: 29.690

3.  Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.

Authors:  Karl Quint; Manuel Tonigold; Pietro Di Fazio; Roberta Montalbano; Susanne Lingelbach; Felix Rückert; Beate Alinger; Matthias Ocker; Daniel Neureiter
Journal:  Int J Oncol       Date:  2012-10-01       Impact factor: 5.650

Review 4.  FOXO transcription factors at the interface between longevity and tumor suppression.

Authors:  Eric L Greer; Anne Brunet
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

5.  Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents.

Authors:  Rama Adikrisna; Shinji Tanaka; Shunsuke Muramatsu; Arihiro Aihara; Daisuke Ban; Takanori Ochiai; Takumi Irie; Atsushi Kudo; Noriaki Nakamura; Shoji Yamaoka; Shigeki Arii
Journal:  Gastroenterology       Date:  2012-04-14       Impact factor: 22.682

6.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.

Authors:  Geng Zhang; Peijun He; Hanson Tan; Anuradha Budhu; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Anirban Maitra; Nader Hanna; H Richard Alexander; S Perwez Hussain
Journal:  Clin Cancer Res       Date:  2013-08-05       Impact factor: 12.531

8.  FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.

Authors:  Andrew Sunters; Silvia Fernández de Mattos; Marie Stahl; Jan J Brosens; Georgia Zoumpoulidou; Catherine A Saunders; Paul J Coffer; René H Medema; R Charles Coombes; Eric W-F Lam
Journal:  J Biol Chem       Date:  2003-10-03       Impact factor: 5.157

9.  Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.

Authors:  Maria Inés Molejon; Juan Ignacio Tellechea; Celine Loncle; Odile Gayet; Marine Gilabert; Pauline Duconseil; Maria Belen Lopez-Millan; Vincent Moutardier; Mohamed Gasmi; Stephane Garcia; Olivier Turrini; Mehdi Ouaissi; Flora Poizat; Nelson Dusetti; Juan Iovanna
Journal:  Oncotarget       Date:  2015-04-10

10.  Pancreatic CSCs and microenvironment.

Authors:  Matthias Ilmer; David Horst
Journal:  Genes Cancer       Date:  2015-09
View more
  22 in total

1.  The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma.

Authors:  Motofumi Kumazoe; Mika Takai; Shun Hiroi; Chieri Takeuchi; Mai Kadomatsu; Takashi Nojiri; Hiroaki Onda; Jaehoon Bae; Yuhui Huang; Kanako Takamatsu; Shuya Yamashita; Kenji Kangawa; Hirofumi Tachibana
Journal:  J Biol Chem       Date:  2017-05-15       Impact factor: 5.157

2.  Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.

Authors:  Tadas K Rimkus; Richard L Carpenter; Sherona Sirkisoon; Dongqin Zhu; Boris C Pasche; Michael D Chan; Glenn J Lesser; Stephen B Tatter; Kounosuke Watabe; Waldemar Debinski; Hui-Wen Lo
Journal:  Cancer Res       Date:  2018-02-20       Impact factor: 12.701

3.  A splice junction-targeted CRISPR approach (spJCRISPR) reveals human FOXO3B to be a protein-coding gene.

Authors:  Evan E Santo; Jihye Paik
Journal:  Gene       Date:  2018-06-18       Impact factor: 3.688

Review 4.  Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.

Authors:  Elvira Pelosi; Germana Castelli; Ugo Testa
Journal:  Biomedicines       Date:  2017-11-18

5.  5-methoxytryptophan alleviates liver fibrosis by modulating FOXO3a/miR-21/ATG5 signaling pathway mediated autophagy.

Authors:  Ming Tong; Qing Zheng; Meng Liu; Liang Chen; Yi-He Lin; Shi-Gang Tang; Yi-Min Zhu
Journal:  Cell Cycle       Date:  2021-03-18       Impact factor: 4.534

6.  PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma.

Authors:  Motofumi Kumazoe; Mika Takai; Shun Hiroi; Chieri Takeuchi; Maasa Yamanouchi; Takashi Nojiri; Hiroaki Onda; Jaehoon Bae; Yuhui Huang; Kanako Takamatsu; Shuya Yamashita; Shuhei Yamada; Kenji Kangawa; Takashi Takahashi; Hiroshi Tanaka; Hirofumi Tachibana
Journal:  Sci Rep       Date:  2017-05-15       Impact factor: 4.379

7.  FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.

Authors:  Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Taku Shigesawa; Gouki Kanbe; Megumi Kimura; Masaya Sugiyama; Masashi Mizokami; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Naoto Okubo; Shunsuke Ohnishi; Hiroshi Takeda; Naoya Sakamoto
Journal:  Cancer Biol Ther       Date:  2021-07-05       Impact factor: 4.875

8.  Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers.

Authors:  Takashi Nojiri; Miki Arai; Yutaka Suzuki; Motofumi Kumazoe; Takeshi Tokudome; Koichi Miura; Jun Hino; Hiroshi Hosoda; Mikiya Miyazato; Meinoshin Okumura; Shinpei Kawaoka; Kenji Kangawa
Journal:  Oncotarget       Date:  2017-05-25

Review 9.  The biology and role of CD44 in cancer progression: therapeutic implications.

Authors:  Chen Chen; Shujie Zhao; Anand Karnad; James W Freeman
Journal:  J Hematol Oncol       Date:  2018-05-10       Impact factor: 17.388

10.  Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.

Authors:  Mi-Ae Kang; Jongsung Lee; Sang Hoon Ha; Chang Min Lee; Kyoung Min Kim; Kyu Yun Jang; See-Hyoung Park
Journal:  Cancers (Basel)       Date:  2019-09-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.